Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans.
about
Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.Vascular actions of 20-HETEAssociation of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese populationEvaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular diseaseCytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncouplingVascular characterization of mice with endothelial expression of cytochrome P450 4F2.Mitochondrial P450-dependent arachidonic acid metabolism by TCDD-induced hepatic CYP1A5; conversion of EETs to DHETs by mitochondrial soluble epoxide hydrolase.Renal function and vasomotor activity in mice lacking the Cyp4a14 gene.The role of 20-HETE in androgen-mediated hypertension.CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependentDetermination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation.20-Hydroxyeicosatetraenoic acid involved in endothelial activation and thrombosis.20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension.PharmGKB summary: very important pharmacogene information for CYP4F2Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kappaB Kinase.Chronic activation of AMP-activated protein kinase prevents 20-hydroxyeicosatetraenoic acid-induced endothelial dysfunction.20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616.Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease.Endothelial dysfunction: its role in hypertensive coronary disease.Hypertension and oxidative stress.20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter BindingAssociation of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension.Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes.An eicosanoid-centric view of atherothrombotic risk factorsAndrogen-sensitive hypertension associated with soluble guanylate cyclase-α1 deficiency is mediated by 20-HETE.The molecular sources of reactive oxygen species in hypertension.Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE.Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.Convenient syntheses of [20,20,20-H(3)]-arachidonic acid and [20,20-H(2)]-20-hydroxyeicosatetraenoic acidInduction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction.Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation.Introgression of Brown Norway CYP4A genes on to the Dahl salt-sensitive background restores vascular function in SS-5(BN) consomic rats.Biomarkers of oxidative damage are elevated among individuals with high cardiovascular risk: refining subject selection strategies for antioxidant trials.Contribution of cytochrome P450 metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME.Arachidonic acid metabolism in glucocorticoid-induced hypertension.Effect of 20-HETE inhibition on L-NAME-induced hypertension in rats.A Novel Polymorphism in the Promoter of the CYP4A11 Gene Is Associated with Susceptibility to Coronary Artery Disease.Elevated 20-HETE impairs coronary collateral growth in metabolic syndrome via endothelial dysfunction.
P2860
Q27343126-1CB6054B-1657-4451-A2B3-2239BBD50646Q28259468-879E836C-C7A2-4F2D-9068-8FA718B63016Q28272355-CD990465-8E15-459A-9488-C26D8A9DB7E7Q28384901-5342F9D6-14EB-4F7A-B9A3-765C4353A294Q28397434-B400BB3A-5C7D-441F-AF3F-D281EC8250ABQ33574917-942366D1-C1CE-46E4-9C60-F56BB76CA0E7Q33775129-1DCD6D79-0E39-4DA5-9B02-AA32E7F59A8EQ33844883-A27EDABA-FECE-4F74-B231-3B928DE86C25Q34143379-187A219F-BD42-49F0-9E1B-6A8D3BB43D9FQ34196923-33CCF1F8-BD2A-41CD-8737-03D5AE613A24Q34369965-2246DA3B-ED74-4BE5-9E78-4D4A3E94CBFAQ34440126-A59F3EF3-C800-4163-9F61-662C01009C1AQ34469211-AE8F0AB6-6E3C-4ADE-ABED-17883D7D5C6CQ34553783-B9ECDC79-53D5-4F8D-BDAF-27C33E4D1687Q34664072-765A87B6-1D54-46A4-A123-F00A1EE4C0C5Q34780122-EEC8D6FC-C34E-4861-835E-7B8EAA05E12EQ34918014-6BA01FC7-B7B2-4E46-81D9-55DD6A29167FQ35157119-0E0C9215-FC75-47E0-82E1-9E5161C964CBQ35404485-6C490538-2779-4C78-B2EA-1CB1915454ABQ35581616-9F55445C-8C61-4DCA-874D-9598B322F35FQ36572712-01E0F712-3400-4C85-B1C1-45FC84B8BB00Q36618716-C094513A-523E-4C14-9DE8-730F5118EF78Q36666897-E87AA3FE-1EF7-4795-A3C0-26624FA932FBQ36744134-7E208DC2-9D37-4A0B-A65C-8042BF998D07Q36952174-8A1356DC-82B1-4040-BFE1-6D4BCE58987CQ37071952-A2B950F7-FAB9-4B38-A9CE-8034A02B8EB2Q37196365-64418FB9-BEDC-4487-B6FC-ED3B45DD71BBQ37340856-8CED7F09-7CE7-48B1-AACD-E3B13B1DC488Q37417272-ADF84519-C7D1-4B1A-831A-4A1E416A86C2Q38693289-4376831C-7F9B-4AE9-9914-47CC7FB422CFQ41915303-0AD6712F-1231-447F-AE3C-60EF3C3254DBQ42115749-91C602DE-31B7-46F1-B22A-993723E3EB02Q42912792-30E9FB90-48B6-4525-85E1-11D8A1C69960Q42954764-51285B3B-57A6-4AA1-9AE2-6293757A5E07Q45148636-95ED7276-A1C0-404F-BAD4-E734BD8A5587Q46714713-CAFDBF22-844C-45A1-933A-7EBBE6E4DA96Q46859788-0B0CE4A2-360E-47D7-85E9-B178419DAEABQ47819353-07335C96-DFB4-4E97-BD0E-4FBFDF772378Q51150942-9000910D-D491-4A6D-B236-00E421619D56Q51239324-7A20B8FE-7DB4-4754-A142-894B4BD9850A
P2860
Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@ast
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@en
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@nl
type
label
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@ast
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@en
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@nl
prefLabel
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@ast
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@en
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@nl
P2093
P1433
P1476
Urinary 20-hydroxyeicosatetrae ...... thelial dysfunction in humans.
@en
P2093
Ian B Puddey
Jennifer Rivera
John R Falck
Jonathan Hodgson
Kevin D Croft
Lawrie J Beilin
Natalie C Ward
P304
P356
10.1161/01.CIR.0000136808.72912.D9
P407
P577
2004-07-19T00:00:00Z